Results 271 to 280 of about 144,316 (318)
Some of the next articles are maybe not open access.
Archives of Internal Medicine, 1973
Erythropoietin (Epo), the first growth factor to be discovered, is an endocrine hormone produced by specialized renal cells. The rate of Epo production is determined primarily by the oxygen demands of these renal cells relative to their oxygen supply.
openaire +3 more sources
Erythropoietin (Epo), the first growth factor to be discovered, is an endocrine hormone produced by specialized renal cells. The rate of Epo production is determined primarily by the oxygen demands of these renal cells relative to their oxygen supply.
openaire +3 more sources
The International Journal of Biochemistry & Cell Biology, 1999
The erythropoietin (epo) receptor is a member of the cytokine receptor family. It is expressed almost exclusively on erythroid precursor cells and controls the development of red blood cells. The epo receptor has no intrinsic kinase activity, but binds intracellular tyrosine kinases to elicit its signals.
P A, Tilbrook, S P, Klinken
openaire +2 more sources
The erythropoietin (epo) receptor is a member of the cytokine receptor family. It is expressed almost exclusively on erythroid precursor cells and controls the development of red blood cells. The epo receptor has no intrinsic kinase activity, but binds intracellular tyrosine kinases to elicit its signals.
P A, Tilbrook, S P, Klinken
openaire +2 more sources
Blut, 1976
Abstract Epo was purified from the urine of anaemic patients(Miyake et al. 1977), and the amino acid sequence derived from the purified protein {Lai et al. 1986) led to the cloning of the human epo gene {Lin et al. 1985; Jacobs et al. 1985).
openaire +2 more sources
Abstract Epo was purified from the urine of anaemic patients(Miyake et al. 1977), and the amino acid sequence derived from the purified protein {Lai et al. 1986) led to the cloning of the human epo gene {Lin et al. 1985; Jacobs et al. 1985).
openaire +2 more sources
Hematology/Oncology Clinics of North America, 1994
The physiology of maternal and fetal erythropoiesis in pregnancy shows that hematopoiesis, and the stimulation of hematopoiesis, take place separately in the two circulations. Erythropoietin appears the main regulator in both mother and fetus. The human placenta forms a manifest barrier to endogenous and recombinant erythropoietin, thus fulfilling the ...
R, Huch, A, Huch
openaire +2 more sources
The physiology of maternal and fetal erythropoiesis in pregnancy shows that hematopoiesis, and the stimulation of hematopoiesis, take place separately in the two circulations. Erythropoietin appears the main regulator in both mother and fetus. The human placenta forms a manifest barrier to endogenous and recombinant erythropoietin, thus fulfilling the ...
R, Huch, A, Huch
openaire +2 more sources
Erythropoietin pathophysiology and erythropoietin deficiency anemia
The Hematology Journal, 2004Review aerticle on erythropoietin pathophysiology and erythropoietin deficiency anemia.
openaire +2 more sources
New England Journal of Medicine, 1971
Studies of the regulation of red-cell production have recently taken on some urgency because of the potential usefulness of erythropoietin in the treatment of patients with anemia due to chronic re...
openaire +2 more sources
Studies of the regulation of red-cell production have recently taken on some urgency because of the potential usefulness of erythropoietin in the treatment of patients with anemia due to chronic re...
openaire +2 more sources
Obstetrical & Gynecological Survey, 1998
Our objective was to discuss the role of erythropoietin in fetal erythropoiesis and to review its clinical uses in perinatal medicine. All relevant articles compiled through a MEDLINE search (years 1986-1997) were reviewed. Erythropoietin is essential for fetal erythropoiesis and is produced in response to hypoxia and anemia.
M, Vora, A, Gruslin
openaire +2 more sources
Our objective was to discuss the role of erythropoietin in fetal erythropoiesis and to review its clinical uses in perinatal medicine. All relevant articles compiled through a MEDLINE search (years 1986-1997) were reviewed. Erythropoietin is essential for fetal erythropoiesis and is produced in response to hypoxia and anemia.
M, Vora, A, Gruslin
openaire +2 more sources
New England Journal of Medicine, 2007
Dialysis facilities can make more money from administering epoetin than from dialysis and related routine services, which Medicare has reimbursed at a composite rate since 1983. Dr. Robert Steinbrook writes that in 2007, Congress may consider whether to eliminate financial incentives that may lead to the overuse of epoetin and other separately billable
openaire +2 more sources
Dialysis facilities can make more money from administering epoetin than from dialysis and related routine services, which Medicare has reimbursed at a composite rate since 1983. Dr. Robert Steinbrook writes that in 2007, Congress may consider whether to eliminate financial incentives that may lead to the overuse of epoetin and other separately billable
openaire +2 more sources
2001
Hypoxia induces tissue-specific gene products such as erythropoietin (EPO) and vascular endothelial growth factor (VEGF), which improve the peripheral O2 supply, and glucose transporters and glycolytic enzymes, which adapt cells to reduced O2 availability. EPO has been the fountainhead in research on pO2-dependent synthesis of proteins.
W, Jelkmann, T, Hellwig-Bürgel
openaire +2 more sources
Hypoxia induces tissue-specific gene products such as erythropoietin (EPO) and vascular endothelial growth factor (VEGF), which improve the peripheral O2 supply, and glucose transporters and glycolytic enzymes, which adapt cells to reduced O2 availability. EPO has been the fountainhead in research on pO2-dependent synthesis of proteins.
W, Jelkmann, T, Hellwig-Bürgel
openaire +2 more sources
Veterinary Clinics of North America: Small Animal Practice, 2003
EPO is a hematopoietic growth factor produced in the kidney that stimulates erythropoiesis. It effectively treats hypoproliferative anemia associated with CRF, improving quality of life in these patients. Other uses that are poorly characterized in veterinary medicine include treatment of cancer patients on chemotherapy, hematologic disorders, and ...
Cathy E, Langston +2 more
openaire +2 more sources
EPO is a hematopoietic growth factor produced in the kidney that stimulates erythropoiesis. It effectively treats hypoproliferative anemia associated with CRF, improving quality of life in these patients. Other uses that are poorly characterized in veterinary medicine include treatment of cancer patients on chemotherapy, hematologic disorders, and ...
Cathy E, Langston +2 more
openaire +2 more sources